Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2206 to 2220 of 8933 results

  1. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

    Awaiting development Reference number: GID-TA10694 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development Reference number: GID-TA11040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]

    Awaiting development Reference number: GID-TA11673 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Bimekizumab for treating ankylosing spondylitis [ID4011]

    Awaiting development Reference number: GID-TA11150 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pridopidine for treating Huntington's disease [ID6525]

    Awaiting development Reference number: GID-TA11637 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]

    Awaiting development Reference number: GID-TA11814 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development Reference number: GID-TA10990 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Elamipretide for treating Barth syndrome in people of any age [ID6545]

    Awaiting development Reference number: GID-TA11719 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]

    Awaiting development Reference number: GID-TA11746 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ruxolitinib for treating moderate atopic dermatitis [ID6602]

    Awaiting development Reference number: GID-TA11809 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development